Recipharm AB

Bespak by Recipharm delivers market leading design, development, and manufacturing services for drug delivery devices to the global pharmaceutical market. Our portfolio includes inhalers, nasal technologies, and auto-injectors as well as development and manufacturing services.

At Recipharm, we offer drug product development services for all common dosage forms. Our team can manage the complexity of your project, helping you find the best solution whether you are looking for development support to take your product to first-in-human (FIH) studies or to advance your product to mar...

Recipharm has more than 25 years’ experience in drug substance development and manufacturing. We are ideally placed to deliver a wide range of drug substance services from our dedicated development facilities around the world.

An integrated service for inhalation drug products and devices spanning early-stage development to commercial manufacture. Our depth of knowledge means we can overcome the challenges associated with inhalation drug products and devices.

Recipharm offer formulation development services for all dosage forms. We develop everything from simple formulations for early studies to more complex formulations suited for commercialisation.

Astrea Pharma will be the new owner of the facility at Fontaine-lès-Dijon

Your innovative drug. Our world-class production facilities. Discover the genius of working together.

We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event.

nhalation development and manufacturing for early and late-stage clinical supply.

Recipharm Inhalation Solutions™ offers comprehensive contract development and manufacturing solutions for early and late-phase clinical supply from our stand-alone pilot plant as part of our integrated inhalation offering.

Lyophilisation or freeze drying is an important means to improve thermal stability of a drug product, according to Thomas Becker, Quality Director and Qualified Person, Recipharm. This is particularly true for those that are thermolabile, such as mRNA vaccine candidates.

Find out how Recipharm developed a suitable analysis method for Lecigon® intestinal gel, a combination drug product containing three active pharmaceutical ingredients.

Hydrofluoroalkane (HFAs), or F-gases, have been used as propellants in metered dose inhalers (MDIs) and other inhalation products for many years. However, due to their high global warming potential (GWP) – 1,430 times that of CO2, the United Nations (UN) has committed to reducing global HFA consumption by 80-85% by 2047, with the aim of slowing global warming (1).

Resyca, a joint venture between Recipharm and Medspray, is developing a novel type of soft mist inhaler devices, based on an existing primary packaging: glass pre filled syringes. This way we can utilise existing filling lines within Recipharm to do the aseptical filling. The lecture will describe the devices and the typical timelines for clinical and commercial supply.

Most pharma and biological companies perform their drug discovery, pre clinical and phase 1 clinical work with nebulisers and liquid formulations. By using a soft mist inhaler device, they can take a shortcut and reach the market sooner and with lower development risks. Resyca's soft mist inhalers have been developed with biologics formulations in mind, being able to deliver milligrams of drug in a single inhalation from a pocket size device.


Click here to register

A summary exploring Recipharm’s key considerations when it comes to developing effective analytical methods for drug projects.

Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and scaling up to the commercial level are just three examples. With so many outsourcing options available, selecting the CDMO that is the right fit for any particular sponsor company can be a challenging task. We speak with Frank Ternes, Chief Commercial Officer and Filip Ringborg, Director Contract Management & Operations Development, at Recipharm on best practice when it comes to selecting the right fit for your outsourcing requirements and how strategic partnerships built on trust are fundamental to success.

With so many outsourcing options available, selecting the CDMO that is the right fit for any particular sponsor company can be a challenging task.

As we approach the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event, we’re looking ahead to what 2022 has in store for the pharma industry. In this 60 minute, free-to-attend webinar, you’ll have the opportunity to hear from market experts from different sectors of the industry on the key trends, dynamics and disruptors we can anticipate in the coming year. Sourcing dynamics, the shift to self-administration, biotech innovation and sustainability are all high on the agenda – join us as we explore where the biggest opportunities and challenges lie and build your knowledge on where the industry is heading.

In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update.

Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and scaling up to the commercial level are just three examples.

In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update. 

The CDMO inaugurates its new analytical laboratory under Recipharm Analytical Solutions

Medalchemy facility now fully licensed to import, cultivate, extract, manufacture and export medical cannabis flower and extracts

Move is part of US$500 million five-year investment programme by Moroccan government and consortium to establish vaccine and biotherapeutic manufacturing capacity in the country

Joint venture between Recipharm and Medspray could provide significant advantages for patients and the environment, companies say

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

The CDMO is already making certain investments to enable technology transfer and scale-up to commence imminently.

Resyca BV will provide a "unique offering" to the market — environmentally friendly, softmist spray nozzle technology for pharmaceutical applications.

The expansion will bolster the CDMO's offering by ensuring it can fulfil the forecasted increase in demand for respiratory devices.

Recipharm is pleased to announce that the results of the study with Erdosteine as an add-on treatment for COVID-19 patients are now available.

The investment will support increased demand and help to secure new business at its Kaysersberg facility.

Global contract development and manufacturing organisation (CDMO), Recipharm, has announced a EUR 2.6 million investment for additional manufacturing capacity to support increased demand into its Kaysersberg facility.

Recipharm, a leading contract development and manufacturing organisation (CDMO) has entered into an agreement with Arcturus Therapeutics, a leading U.S. based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.